Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease

Palhagen, S. E. ; Dizdar, N. ; Hauge, T. ; Holmberg, B. ; Jansson, R. ; Linder, J. ; Nyholm, D. ; Sydow, O. ; Wainwright, M. and Widner, Håkan LU , et al. (2012) In Acta Neurologica Scandinavica 126(6). p.29-33
Abstract
Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD),... (More)
Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD), baseline = 52.1 +/- 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 +/- 16.7, N = 27, P = 0.003; month 12 = 42.5 +/- 22.6, n = 25, P = 0.017. PDQ-39 results also showed a tendency for improvement: PDQ-39 (mean +/- SD), baseline = 33.6 +/- 10.8, N = 27, month 0 = 27.1 +/- 11.8, N = 27, P = 0.001; 12 months = 28.8 +/- 12.8, n = 23, P = 0.126. Conclusions - LCIG provides functional improvement beginning at first visit that is sustained for 12 months. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
movement disorders, Parkinson's disease, quality of life, treatment
in
Acta Neurologica Scandinavica
volume
126
issue
6
pages
29 - 33
publisher
Wiley-Blackwell
external identifiers
  • wos:000310545400001
  • scopus:84868190961
  • pmid:22690905
ISSN
1600-0404
DOI
10.1111/j.1600-0404.2012.01689.x
language
English
LU publication?
yes
id
69c25a97-7e13-4953-8712-24bbf00347e2 (old id 3283349)
date added to LUP
2016-04-01 13:14:10
date last changed
2022-05-15 03:23:40
@article{69c25a97-7e13-4953-8712-24bbf00347e2,
  abstract     = {{Background - This interim 12-month analysis is a part of an open-label, observational, prospective study on health outcomes and cost impact of levodopa/carbidopa intestinal gel (LCIG, Duodopa) in Parkinson disease (PD). The specific aim was to investigate clinical and health-related quality of life (HRQoL) effects in routine care. Methods - Unified PD rating scale (UPDRS) was the primary efficacy measurement. PD QoL questionnaire 39 (PDQ-39) assessed HRQoL. Subjects were assessed at baseline, >= 3 months after surgery, and then every 3 months. Results - Twenty-seven treatment-naive subjects when started with LCIG showed a decrease in UPDRS score that was statistically significant throughout the year: UPDRS total score (mean +/- SD), baseline = 52.1 +/- 16.1, N = 27, month 0 (first visit; at least 3 months after permanent LCIG) = 43.1 +/- 16.7, N = 27, P = 0.003; month 12 = 42.5 +/- 22.6, n = 25, P = 0.017. PDQ-39 results also showed a tendency for improvement: PDQ-39 (mean +/- SD), baseline = 33.6 +/- 10.8, N = 27, month 0 = 27.1 +/- 11.8, N = 27, P = 0.001; 12 months = 28.8 +/- 12.8, n = 23, P = 0.126. Conclusions - LCIG provides functional improvement beginning at first visit that is sustained for 12 months.}},
  author       = {{Palhagen, S. E. and Dizdar, N. and Hauge, T. and Holmberg, B. and Jansson, R. and Linder, J. and Nyholm, D. and Sydow, O. and Wainwright, M. and Widner, Håkan and Johansson, A.}},
  issn         = {{1600-0404}},
  keywords     = {{movement disorders; Parkinson's disease; quality of life; treatment}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{29--33}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Acta Neurologica Scandinavica}},
  title        = {{Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease}},
  url          = {{http://dx.doi.org/10.1111/j.1600-0404.2012.01689.x}},
  doi          = {{10.1111/j.1600-0404.2012.01689.x}},
  volume       = {{126}},
  year         = {{2012}},
}